AZD9496: An oral estrogen receptor inhibitor that blocks the growth of ER-positive and ESR1-mutant breast tumors in preclinical models

Cancer Research

Volumn 76, Issue 11, 2016, Pages 3307-3318

  Weir, Hazel M ^a   Bradbury, Robert H ^a   Rabow, Alfred A ^a   Buttar, David ^a   Callis, Rowena J ^a   Curwen, Jon O ^a   De Almeida, Camila ^a   Ballard, Peter ^a   Hulse, Michael ^a   Donald, Craig S ^a   Feron, Lyman J L ^a   Karoutchi, Galith ^a   MacFaul, Philip ^a   Moss, Thomas ^a   Norman, Richard A ^a   Pearson, Stuart E ^a   Tonge, Michael ^a   Davies, Gareth ^a   Walker, Graeme E ^a   Wilson, Zena ^a   Rowlinson, Rachel ^a   Powell, Steve ^a   Sadler, Claire ^a   Richmond, Graham ^a   Ladd, Brendon ^a   Pazolli, Ermira ^b   Mazzola, Anne Marie ^a   D'Cruz, Celina ^a   De Savi, Chris ^a   more..

^a ASTRAZENECA   (United Kingdom)

^b EISAI INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 9496; ESTROGEN RECEPTOR ANTAGONIST; FULVESTRANT; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG; AZD9496; CINNAMIC ACID DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; INDOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG HALF LIFE; DRUG POTENCY; ESR1 GENE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; GENETICS; METABOLISM; MUTATION; NONOBESE DIABETIC MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; PRECLINICAL STUDY; PROTEIN CONFORMATION; SCID MOUSE; TUMOR CELL CULTURE; UTERUS;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; CINNAMATES; DRUG EVALUATION, PRECLINICAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INDOLES; MICE; MICE, INBRED NOD; MICE, SCID; MUTATION; PROTEIN CONFORMATION; RATS; TUMOR CELLS, CULTURED; UTERUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84975060972     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2357     Document Type: Article

References (49)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
2. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010;11:1135-41.
3. Nicholson RI, Hutcheson IR, Jones HE, Hiscox SE, Giles M, Taylor KM, et al. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer. Rev Endocr Metab Disord 2007;8:241-53.
4. Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 2010;24:2219-27.
5. Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocr Relat Cancer 2006;13Suppl 1:S15-24.
6. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002;2:101-12.
7. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 2014;106:337.
8. Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat 2012;133:237-46.
9. Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI, Kuter I, et al. A good drug made better: the fulvestrant dose-response story. Clin Breast Cancer 2014;14:381-9.
10. Robertson JF, Harrison M. Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer 2004;90Suppl 1:S7-10.
11. Howell A, Sapunar F. Fulvestrant revisited: efficacy andsafetyof the 500-mg dose. Clin Breast Cancer 2011;11:204-10.
12. Robertson JF. Fulvestrant (Faslodex) - how to make a good drug better. Oncologist 2007;12:774-84.
13. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breastcancer-derived xenografts. Cell Rep 2013;4:1116-30.
14. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013;45:1439-45.
15. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 2014;20:1757-67.
16. Willson TM, Henke BR, Momtahen TM, Charifson PS, Batchelor KW, Lubahn DB, et al. 3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic acid: a non-steroidal estrogen with functional selectivity for bone over uterus in rats. J Med Chem 1994;37:1550-2.
17. Hoffmann J, Bohlmann R, Heinrich N, Hofmeister H, Kroll J, Kunzer H, et al. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer. J Natl Cancer Inst 2004;96:210-8.
18. Tan Q, Blizzard TA, Morgan JD, Birzin ET, Chan W, Yang YT, et al. Estrogen receptor ligands. Part 10: Chromanes: old scaffolds for new SERAMs. Bioorg Med Chem Lett 2005;15:1675-81.
19. Suzuki N, Liu X, Laxmi YR, Okamoto K, Kim HJ, Zhang G, et al. Anti-breast cancer potential of SS5020, a novel benzopyran antiestrogen. Int J Cancer 2011;128:974-82.
20. Lai A, Kahraman M, Govek S, Nagasawa J, Bonnefous C, Julien J, et al. Identification of GDC-0810 (ARN-810), an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. J Med Chem 2015;58:4888-904.
21. Garner F, Shomali M, Paquin D, Lyttle R, Hattersley G. RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumour activity in breast cancer xenograft models. Anti-Cancer Drugs 2015;26:948-956.
22. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, et al. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res 2011;17:2024-34.
23. Callis R, Rabow A, Tonge M, Bradbury R, Challinor M, Roberts K, et al. A screening assay cascade to identify and characterize novel selective estrogen receptor downregulators (SERDs). J Biomol Screen 2015;20:748-59.
24. Degorce SL, Bailey A, Callis R, De Savi C, Ducray R, Lamont G, et al. Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic acids as oral selective estrogen receptor down-regulators. J Med Chem 2015;58:3522-33.
25. Kabsch W. Xds. Acta Crystallogr D Biol Crystallogr 2010;66:125-32.
26. Incardona MF, Bourenkov GP, Levik K, Pieritz RA, Popov AN, Svensson O. EDNA: a framework for plugin-based applications applied to X-ray experiment online data analysis. J Synchrotron Radiat 2009;16:872-9.
27. Evans P. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 2006;62:72-82.
28. Navaza J. Implementation of molecular replacement in AMoRe. Acta Crystallogr D Biol Crystallogr 2001;57:1367-72.
29. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 2010;66:486-501.
30. Ong S, Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc 2007;1:2650-60.
31. Wakeling AE, O'Connor KM, Newboult E. Comparison of the biological effects of tamoxifen and a new antioestrogen (LY 117018) on the immature rat uterus. J Endocrinol 1983;99:447-53.
32. Bradbury R, De Savi C, Rabow A, Norman R, de Almeida C, Andrews D. Optimization of a novel binding motif to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist. J Med Chem 2015;58:8128-40.
33. Wu YL, Yang X, Ren Z, McDonnell DP, Norris JD, Willson TM, et al. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Mol Cell 2005;18:413-24.
34. Horwitz KB, McGuire WL. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. J Biol Chem 1978;253:2223-8.
35. Rich RL, Hoth LR, Geoghegan KF, Brown TA, LeMotte PK, Simons SP, et al. Kinetic analysis of estrogen receptor/ligand interactions. Proc Natl Acad Sci U S A 2002;99:8562-67.
36. Pike AC, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 1999;18:4608-18.
37. Grese TA, Sluka JP, Bryant HU, Cullinan GJ, Glasebrook AL, Jones CD, et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci U S A 1997;94:14105-10.
38. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 2000;5:939-48.
39. Reid G, Hübner MR, Métivier R, Brand H, Denger S, Manu D, et al. Cyclic, proteosome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol Cell 2003;11:695-707.
40. Ghosh MG, Thompson DA, Weigel RJ. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res 2000;60:6367-75.
41. Sauve K, Lepage J, Sanchez M, Heveker N, Tremblay A. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Cancer Res 2009;69:5793-800.
42. Vendrell JA, Magnino F, Danis E, Duchesne MJ, Pinloche S, Pons S, et al. Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol 2004;32:397-414.
43. Austreid E, Lonning PE, Eikesdal HP. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opin Pharmacother 2014;15:681-700.
44. Liu H, Park W, Bentrem DJ, McKian KP, De Los Reyes A, Loweth JA, et al. Structure-function relationship of the raloxifene-estrogen receptor-α complex for regulating transforming growth factor-α in breast cancer cells. J Biol Chem 2002;277:9189-98.
45. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013;381:805-16.
46. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000;356:881-7.
47. Folkerd E, Dowsett M. Sex hormones and breast cancer risk and prognosis. Breast 2013;22Suppl 2:S38-43.
48. Sen T, Li S, Shao J, Crowder R, Kitchen R, Ellis MJ. Patient-derived xenograft study reveals the pharmacology and the role of ESR1 gene aberrations in endocrine therapy resistance of ER positive breast cancer. Can Res 2014;74:5544.
49. Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, et al. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol 2014;25:2357-62.